emerging markets

Podcast brought to you by: Chempetitive Group - Who for more than a decade has helped science-based companies build and execute innovative marketing campaigns. "We love science. We love marketing. We love the idea of combining the two to make great things happen for your marketing communications."

Guest:

Marco A. Biamonte, CEO, Drug Discovery for Tropical Diseases Bio and Contact Info

Every once in a while a story comes along that sounds too good to be true. You do a double take and ask, did I hear that right? Marco Biamonte is from the French speaking area of Switzerland. In his early 20’s he traveled around the world, particularly the third world, as many youngsters do. There he encountered poverty and disease which startled him. And which he has never forgotten. Twenty years later, after a career as a chemist at Biogen Idec, Biamonte is returning to the compassion he found in his youth that came as a result of exposure to those less fortunate. Now, after years in the pharma industry, he feels empowered and equipped to do something to relieve the suffering of so many.

Marco is the founder of Drug Discovery for Tropical Diseases, a non profit based in San Diego that is striking out against diseases associated with poverty. And their first project is to develop a better medication for malaria. What about the work of the Gates Foundation in this area, or other non profits, I ask Biamonte, and where did he find the confidence to strike out on his own in such an undertaking? How is the organization funded, and how will the enterprise fare in a profit driven industry? Listen to the answers in Marco's own words.

Podcast Sponsor: Audacity - Building health and science brand supremacy through disruptive marketing and advertising. Download "4 Secrets to Brand Supremacy," for free www.audacityhealth.com/approach

1:08 Population specific genomics

7:03 Personalized medicine and diagnostics abroad

16:15 Agbio

20:02 Are arrays still more widespread than sequencing worldwide?

27:11 What's the most obscure place where you've promoted arrays?

31:00 Personal path to international markets

34:57 Worst airport story ever

Chris Barbazette is Affymetrix's VP for International Markets. He travels the equivalent of the distance around the globe each month. He joins us to talk about what's going on in genomics in such places as Saudi Arabia and China. Are arrays still the most important genomic technology abroad? Where's the most obscure place he's been for work? These are some of the questions we ask in this fun overview.

Podcast brought to you by: Assay Depot - the world's largest cloud-based marketplace for research services. With Assay Depot, you can easily find the perfect research service provider and manage your project from anywhere in the world.

Guest:

Steve Burrill, CEO, Burrill and Co. Bio and Contact Info

Chapters (Move marker to advance)

0:58 Is there a connection between innovation and austerity?

8:58 Consequences of the world's aging population

13:57 Ramifications of upcoming Supreme Court decision on Affordable Care Act

17:41 Opportunities abroad

25:40 Challenges abroad

31:21 AliveCor and Digital Health

39:03 A biologic on track to be world's top selling drug

Today we’re at the offices of Burrill and Co with CEO, Steve Burrill. Steve hardly needs an introduction in our industry. He was an early pioneer of biotech and helped set up such companies as Genentech and Cetus. Each year Burrill and Co. publishes a book on the state of the industry. It’s a complete almanac of information from what’s going on in such places as Singapore and Brazil to the digital health boom happening right here at home. More importantly it’s not just information, but a comprehensive guide to the industry and full of insight. Steve is more comfortable talking about the future than anyone I know. Today he challenges us with the notion that innovation can come at a time of austerity, and downplays the ramifications of the upcoming Supreme Court decision on the Affordable Care Act of 2010. Burrill also discusses a company he's recently invested in and whose board he chairs, AliveCor and makes his own projections of the rapidly growing industry of digital health.

Support mendelspod.com by purchasing Steve's book, "Innovating in the New Austerity," here.

This podcast was originally aired on October 27th, 2011

Sponsored by: BioConference Live

Guest:

Greg Scott, Founder and President of ChinaBio(R) LLC, Bio and Contact Info

Listen (9:53) About ChinaBio

Listen (10:00) Executive retreat 1st of its kind

Listen (4:11) China becoming no.1 market for pharma

Listen (9:25) Innovation

Listen (6:20) Will China soon have a Steve Jobs?

Listen (3:34) What is the opportunity for American businesses?

Listen (7:46) Life in China for the American

Listen (1:42) China doesn't need our help, we need theirs

In 2007, biotech angel investor Greg Scott started ChinaBio to connect China’s life science community with the world, which has helped large, multinational companies such as Pfizer, Roche and Life Technologies, and smaller domestic Chinese companies achieve success in China. ChinaBio has organized 20 conferences, and has generated $400M in funding.   Greg puts out a widely read newsletter on China’s life science industry, ChinaBio® Today. 

This podcast was originally aired on Sept. 14th, 2011

Sponsored by: BioConference Live

Guest:

Dr. Howard McLeod, Director, PGENI, Bio and Contact Info

Listen (8:13) PGENI - Pharmacogenomics for Every Nation Initiative

Listen (2:27) Piggybacking on HIV education

Listen (7:56) Eight active centers around the world

Listen (5:25) Examples of pharmacogenomics

Listen (3:25) FDA coming aboard

Listen (2:03) PGI at UNC: an interdisciplinary approach

Listen (3:44) The promise of lowering healthcare costs

Listen (3:44) Other ways to use the genome

Our guest today is Dr. Howard McLeod, an internationally recognized expert in pharmacogenomics. He’s the director for the UNC Institute for Pharmacogenomics and Individualized Therapy. He’s a member of the FDA’s subcommittee on Clinical Pharmacology, and is the director of the new PGENI, or Pharmacogenomics for Every Nation Initiative. Howard feels he has reached the highest career positions possible and now works to move along the field of pharmacogenomics in the best way possible.